Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Hims & Hers stock rises 14% as FDA schedules peptide compounding review [Yahoo! Finance]

Hims & Hers Health, Inc. Class A (HIMS) 
Company Research Source: Yahoo! Finance
Hims & Hers Health stock rose 13.7%, with premarket trading adding another 9.6% the next morning, MarketWatch reported. The FDA peptide review will cover BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon, with recommendations non-binding. Hims & Hers said peptides are a target category, and its chief medical officer called the FDA's clarity an avenue toward trusted channels. In 2023 the FDA removed 19 peptides over safety risks; supporters seek broader access while critics warn of weak evidence and threats to drug standards. Show less Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for HIMS alerts
Opt-in for
HIMS alerts

from News Quantified
Opt-in for
HIMS alerts

from News Quantified